The Latest
-
Salwan Georges via Getty Images
The Democrats are coming. Here’s how they want to change pharma and healthcare.
This week’s slate of Democratic winners have set their sights on expanding healthcare, removing RFK Jr. from HHS and pulling back the curtain on Trump’s secretive pharma deals.
-
Permission granted by Cytiva
Sponsored by CytivaHow can we build trust in model-driven manufacturing?
Predict, optimize and act sooner with model-driven bioprocessing.
-
Sarah Silbiger via Getty Images
A push for speedier drug approvals doesn’t promise smooth market sailing
Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these medications while they’re still in development.
-
Jamie McCarthy via Getty Images
Lilly’s R&D whirlwind — what the large pharma has taken in and what it’s dropped
While its GLP-1 franchise is still booming, prospects in other arenas haven’t panned out. Here’s a look at where Lilly’s investing the candidates it’s recently had to drop.
-
Permission granted by Johnson & Johnson
Q&AHow well is J&J’s incubator model working?
After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more targeted approach to new science.
-
Permission granted by Merck & Co.
Keytruda biosims are coming — but they face an uphill battle
The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
-
Heather Diehl/Getty Images via Getty Images
Pharma has friends in both parties this midterm season. Neither is offering a free pass.
As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could complicate its traditional campaign playbook.
-
Getty Images
Anthropic’s historic IPO; Akeso’s big clinical showing
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
-
Alamy
Court rejects Novo bid to block Lilly obesity drug ads
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.
-
Getty Images
What a cancer survivor sees that AI could miss in trial design
Parexel’s Stacy Hurt draws on her experience with chemotherapy and as a caregiver to spot patient burdens that AI-assisted protocol design can overlook.
-
Getty Images
What 3 multibillion dollar biotechs still have to prove
Summit, Abivax and Viking have lofty valuations but no FDA-approved products. Each faces a different test of its clinical promise and commercial potential.
-
Permission granted by Courtesy of Immunic Therapeutics
MS has plenty of drugs. This Ocrevus veteran sees what’s missing.
After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting Immunic's experimental drug can address persistent gaps in MS care, with pivotal trial results approaching.
-
Getty Images
A cancer drug worked in the lab — but not how scientists thought
Researchers uncovered the unexpected mechanism behind a cancer drug candidate, highlighting a persistent problem in drug discovery.
-
Getty Images
Most new drugs are still too costly at launch, ICER says
A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
-
Getty Images
Drug discovery is speeding up. But clinical trials are buckling under their own weight.
A growing pipeline is colliding with tougher recruitment, more demanding protocols and trial operations struggling to keep pace — and AI alone can’t fix it.
-
Pete Marovich via Getty Images
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…
Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.
-
Getty Images
Pharma gift giving linked to writing more prescriptions — but less appropriate prescribing
The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors prescribe, according to a new analysis.
-
Getty Images
Biotech is booming — and startups are still dying
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
-
Getty Images
Q&AAlzheimer’s trials need patients. Why are so many screened out?
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.
-
Getty Images
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
-
Getty Images
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
-
Getty Images
Q&A // Biotech SpotlightA new startup takes aim at a suspected culprit in autoimmune disease
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.
-
Getty Images
Pharma’s manufacturing boom has a workforce problem
Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers to run them.
-
Getty Images
Lilly is fighting a black market for its new obesity drug even before it launches
The large pharma’s promising new candidate retatrutide is still in the clinic. But Lilly is already fighting a web of illicit sellers for the drug online.
-
Permission granted by Merck & Co.
ProfileA day in the life of a Merck R&D chief
Dr. Eliav Barr pulls back the curtain on what it's like to manage Merck’s fast-growing pipeline.
-
Getty Images
HHS’ need for R&D speed; weird GLP-1 side effects
HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs.
